OFLOXACIN (Page 2 of 10)
MICROBIOLOGY
Ofloxacin is a quinolone antimicrobial agent. The mechanism of action of ofloxacin and other fluoroquinolone antimicrobials involves inhibition of bacterial topoisomerase IV and DNA gyrase (both of which are type II topoisomerases), enzymes required for DNA replication, transcription, repair and recombination.
Ofloxacin has in vitro activity against a wide range of gram-negative and gram-positive microorganisms. Ofloxacin is often bactericidal at concentrations equal to or slightly greater than inhibitory concentrations.
Fluoroquinolones, including ofloxacin, differ in chemical structure and mode of action from aminoglycosides, macrolides and β -lactam antibiotics, including penicillins. Fluoroquinolones may, therefore, be active against bacteria resistant to these antimicrobials.
Resistance to ofloxacin due to spontaneous mutation in vitro is a rare occurrence (range: 10-9 to 10-11). Although cross-resistance has been observed between ofloxacin and some other fluoroquinolones, some microorganisms resistant to other fluoroquinolones may be susceptible to ofloxacin.
Ofloxacin has been shown to be active against most strains of the following microorganisms both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section:
Aerobic Gram-Positive Microorganisms
Staphylococcus aureus (methicillin-susceptible strains)
Streptococcus pneumoniae (penicillin-susceptible strains)
Streptococcus pyogenes
Aerobic Gram-Negative Microorganisms
Citrobacter (diversus) koseri
Enterobacter aerogenes
Escherichia coli
Haemophilus influenzae
Klebsiella pneumoniae
Neisseria gonorrhoeae
Proteus mirabilis
Pseudomonas aeruginosa
As with other drugs in this class, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ofloxacin.
Other Microorganisms
Chlamydia trachomatis
The following in vitro data are available, but their clinical significance is unknown.
Ofloxacin exhibits in vitro minimum inhibitory concentrations (MIC values) of 2 mcg/mL or less against most (≥ 90%) strains of the following microorganisms; however, the safety and effectiveness of ofloxacin in treating clinical infections due to these microorganisms have not been established in adequate and well-controlled trials.
Aerobic Gram-Positive Microorganisms
Staphylococcus epidermidis (methicillin-susceptible strains)
Staphylococcus saprophyticus
Streptococcus pneumoniae (penicillin-resistant strains)
Aerobic Gram-Negative Microorganisms
Acinetobacter calcoaceticus
Bordetella pertussis
Citrobacter freundii
Enterobacter cloacae
Haemophilus ducreyi
Klebsiella oxytoca
Moraxella catarrhalis
Morganella morganii
Proteus vulgaris
Providencia rettgeri
Providencia stuartii
Serratia marcescens
Anaerobic Microorganisms
Clostridium perfringes
Other Microorganisms
Chlamydia pneumoniae
Gardnerella vaginalis
Legionella pneumophila
Mycoplasma hominis
Mycoplasma pneumoniaeUreaplasma urealyticum
Ofloxacin is not active against Treponema pallidum (see WARNINGS).
Many strains of other streptococcal species, Enterococcus species, and anaerobes are resistant to ofloxacin.
Susceptibility Tests
Dilution Techniques
Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MIC values). These MIC values provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MIC values should be determined using a standardized procedure. Standardized procedures are based on a dilution method1,3 (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of ofloxacin powder. The MIC values should be interpreted according to the following criteria:
MIC (mcg/mL) | Interpretation |
---|---|
≤ 2 | Susceptible (S) |
4 | Intermediate (I) |
≥ 8 | Resistant (R) |
MIC (mcg/mL) | Interpretation |
---|---|
| |
≤ 2 | Susceptible (S) |
The current absence of data on resistant strains precludes defining any results other than “Susceptible.” Strains yielding MIC results suggestive of a “nonsusceptible” category should be submitted to a reference laboratory for further testing.
MIC (mcg/mL) | Interpretation |
---|---|
| |
≤ 0.25 | Susceptible (S) |
0.5 to 1 | Intermediate (I) |
≥ 2 | Resistant (R) |
MIC (mcg/mL) | Interpretation |
---|---|
| |
≤ 2 | Susceptible (S) |
4 | Intermediate (I) |
≥ 8 | Resistant (R) |
A report of “Susceptible” indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentration usually achievable. A report of “Intermediate” indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where a high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of “Resistant” indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentration usually achievable; other therapy should be selected.
Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures. Standard ofloxacin powder should provide the following MIC values:
Microorganism | MIC Range (mcg/mL) | |
---|---|---|
| ||
Escherichia coli | ATCC 25922 | 0.015 to 0.12 |
Haemophilus influenzae | ATCC 49247* | 0.016 to 0.06 |
Neisseria gonorrhoeae | ATCC 49226† | 0.004 to 0.016 |
Pseudomonas aeruginosa | ATCC 27853 | 1 to 8 |
Staphylococcus aureus | ATCC 29213 | 0.12 to 1 |
Streptococcus pneumoniae | ATCC 49619‡ | 1 to 4 |
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.